Evidence map›Paper›PMID 18602395›Full record

ArticleGastroenterology2008

Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients.

Frank Diehl, Kerstin Schmidt, Kristine H Durkee, Kent J Moore, Steve N Goodman, Anthony P Shuber, Kenneth W Kinzler, Bert Vogelstein

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Gastroenterology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

90 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer.European journal of cancer (Oxford, England : 1990) · 2015
    Trial
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Network approach in liquidomics landscape.Journal of experimental & clinical cancer research : CR · 2023
    Review
  12. Evaluation ofCells · 2023
    Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
    Review
  18. Article
  19. Review
  20. Article

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Frank DiehlThe Ludwig Center for Cancer Genetics and Therapeutics, Howard Hughes Medical Institute and Sidney Kimmel Cancer Center, Baltimore, Maryland, USA.
Kerstin Schmidt
Kristine H Durkee
Kent J Moore
Steve N Goodman
Anthony P Shuber
Kenneth W Kinzler
Bert Vogelstein

Funding

Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI LENNON, ANNE MARIE · 1993 to 2022
$54.6M
MOLECULAR GENETIC ANALYSIS OF COLORECTAL CANCERR37CA043460 · NCI · JOHNS HOPKINS UNIVERSITY · PI VOGELSTEIN, BERT · 1997 to 2016
$7.4M
Genes from the FAP LocusR37CA057345 · NCI · JOHNS HOPKINS UNIVERSITY · PI KINZLER, KENNETH W. · 2002 to 2016
$7.4M
Phase I study of Clostridium novyi-NT spores in solid tumor cancer patientsR01CA129825 · NCI · JOHNS HOPKINS UNIVERSITY · PI DIAZ, LUIS A · 2007 to 2010
$1.2M
GENES FROM THE FAP LOCUSR01CA057345 · NCI · JOHNS HOPKINS UNIVERSITY · PI KINZLER, KENNETH W. · 1992 to 2001
$734k
THE P53 GENE IN HUMAN NEOPLASIAR01CA043460 · NCI · JOHNS HOPKINS UNIVERSITY · PI VOGELSTEIN, BERT · 1986 to 1995
–
Howard Hughes Medical InstituteNCI NIH HHS CA129825NCI NIH HHS CA43460NCI NIH HHS CA57345NCI NIH HHS CA62924NCI NIH HHS P50 CA062924NCI NIH HHS R01 CA057345NCI NIH HHS R01 CA129825NCI NIH HHS R37 CA043460NCI NIH HHS R37 CA057345
6 · The paper itself

Abstract

BACKGROUND &

aimsSomatic mutations provide uniquely specific markers for the early detection of neoplasia that can be detected in DNA purified from plasma or stool of patients with colorectal cancer. The primary purpose of the present investigation was to determine the parameters that were critical for detecting mutations using a quantitative assay. A secondary purpose was to compare the results of plasma and stool DNA testing using the same technology.

methodsWe examined DNA purified from the stool of 25 patients with colorectal cancers before surgery. In 16 of these cases, plasma samples also were available. Mutations in stool or plasma were assessed with an improved version of the BEAMing technology.

resultsOf the 25 stool DNA samples analyzed, 23 (92%) contained mutations that were present in the corresponding tumors from the same patients. In contrast, only 8 of the 16 (50%) plasma DNA samples analyzed had detectable levels of mutated DNA. We found that the DNA fragments containing mutations in both stool and plasma DNA typically were smaller than 150 bases in size. The sensitivity of the new method was superior to a widely used technique for detecting mutations, using single base extension and sequencing, when assessed on the same samples (92% vs 60%; P = .008, exact McNemar test).

conclusionsWhen assessed with sufficiently sensitive methods, mutant DNA fragments are detectable in the stool of more than 90% of colorectal cancer patients. DNA purified from stool provides a better template for mutation testing than plasma.

Indexed as

Gene Expression Regulation, NeoplasticMutationAgedAged, 80 and overColorectal NeoplasmsDNA Mutational AnalysisDNA, NeoplasmEmulsionsFecesFemaleFlow CytometryHumansMagneticsMaleMiddle AgedPredictive Value of TestsDNA, NeoplasmEmulsions

Identifiers

PMID18602395
PMCPMC2820386

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.